INIS
patients
100%
antibodies
84%
thrombin
81%
anticoagulants
75%
comparative evaluations
69%
evaluation
53%
women
51%
reviews
49%
covid-19
48%
performance
47%
risks
45%
proteins
45%
plasma
43%
levels
43%
laboratories
33%
vaccines
32%
values
32%
control
32%
estrogens
30%
testing
29%
viruses
27%
doses
26%
administration
26%
populations
25%
immunity
23%
diseases
23%
sensitivity
23%
messenger-rna
22%
in vitro
21%
antigens
20%
coronaviruses
19%
concentration
19%
data
18%
information
17%
capacity
16%
mutations
16%
receptors
15%
biological markers
14%
assessments
14%
investigations
14%
prothrombin
13%
workers
13%
hormones
13%
pregnancy
12%
hemostatics
12%
thrombosis
12%
interventions
12%
kinetics
12%
range
12%
fractures
11%
men
11%
muscles
11%
mortality
11%
emergencies
11%
surfaces
11%
detection
11%
thromboplastin
10%
nucleosomes
10%
peaks
10%
neutrophils
10%
geometry
10%
liquids
9%
cytokines
9%
algorithms
9%
humans
9%
chemistry
9%
lungs
9%
biopsy
9%
dexamethasone
9%
influenza
9%
dimers
9%
durability
9%
lipids
9%
metabolism
9%
lupus
9%
transplants
9%
ablation
9%
accuracy
9%
wave forms
9%
glioblastomas
9%
medicine
9%
bones
9%
screening
9%
hemophilia
9%
osteoporosis
9%
validation
9%
vitamin d
9%
metabolites
9%
balances
9%
blood
9%
symptoms
9%
therapy
8%
speed
7%
heparin
7%
production
7%
safety
7%
genetics
7%
sex
7%
histones
6%
inflammation
6%
carbohydrates
6%
inhibition
6%
mass spectrometry
6%
guidelines
6%
adults
6%
venoms
5%
prophylaxis
5%
Keyphrases
Bivalent Boosters
18%
Breakthrough Infection
13%
XBB.1.5
13%
Subvariant
11%
SARS-CoV-2 Omicron
9%
Cytokine Response
9%
Clinical Performance Evaluation
9%
Rapid Antigen
9%
Pseudotyped Virus
9%
SARS-CoV-2 Neutralizing Antibody
9%
Measurement Analysis
9%
Breakthrough Cases
9%
Moderna mRNA-1273
9%
Atrial Fibrillation Ablation
9%
Randomized Double-blind Study
9%
Liquid Biopsy
9%
Panel Review
9%
D-dimer Assay
9%
ChAdOx1 nCoV-19
9%
Bone Turnover
9%
Clinical Chemistry
9%
COVID-19 Breakthrough Infections
9%
Strip Test
9%
Diagnostic Test Accuracy
9%
N Antigen
9%
Anticoagulant Effect
9%
Rivaroxaban
9%
Neutralizing Antibodies
9%
In Vitro Study
9%
BNT162b2
9%
Literature Review Analysis
9%
AZD7442
9%
Cilgavimab
9%
Tixagevimab
9%
Combined Oral Contraceptives
9%
Vitamin D Metabolite Ratio
9%
EudraVigilance Database
9%
Venous Thromboembolic Events
9%
Delphi Consensus
9%
Natural Estrogens
9%
Disproportionality Analysis
9%
Ethinylestradiol
9%
Omicron Sub-lineages
9%
Geometric Mean Titer
8%
Omicron Variant
6%
Factor V Leiden mutation
6%
Anti-RBD IgG
5%
Reporting Rate
5%
D614G
5%
Emicizumab
5%